Rebecca Chambers
Chief Financial Officer; Director · 6 filings · Latest: Jun 2, 2026
Alamar Biosciences, Inc.
VERACYTE, INC.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
VCYT | Rebecca Chambers | Chief Financial Officer | Jun 4, 2026 | Sale | $49.73 | 3,561 | $177.1K | 173,280 | |
VCYT | REBECCA CHAMBERS | — | Jun 4, 2026 | Proposed Sale | $48.69 | 3,561 | $173.4K | — | |
VCYT | Rebecca Chambers | Chief Financial Officer | Mar 4, 2026 | Sale | $36.14 | 18,341 | $662.9K | 131,196 | |
VCYT | REBECCA CHAMBERS | — | Mar 4, 2026 | Proposed Sale | $35.08 | 18,341 | $643.4K | — | |
VCYT | REBECCA CHAMBERS | — | Dec 4, 2025 | Proposed Sale | $47.75 | 13,278 | $634.0K | — | |
VCYT | REBECCA CHAMBERS | — | Nov 5, 2025 | Proposed Sale | $36.12 | 7,000 | $252.8K | — | |
VCYT | REBECCA CHAMBERS | — | Dec 3, 2024 | Proposed Sale | $44.12 | 7,527 | $332.1K | — | |
VCYT | REBECCA CHAMBERS | — | Nov 12, 2024 | Proposed Sale | $38.89 | 15,275 | $594.0K | — |